The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2013IL-13Ra1 and Neuroinflammatory Damage in the MPTP Pre-Clinical Model of PD
Study Rationale:
Neuroinflammation has been proposed to contribute to both the pathogenesis and the progression of Parkinson's disease (PD). We recently showed that an important... -
LRRK2 Role in Idiopathic Parkinson's Disease, 2013Phenotype Assay for LRRK2 in Parkinson's Disease Fibroblasts
Objective/Rationale:
Variants of the LRRK2 gene are associated with overactivation of the LRRK2 protein’s activity and an increased risk of Parkinson's disease (PD). We have previously... -
LRRK2 Challenge, 2013Investigating the Role of LRRK2 in Mycobacterial Infection
Objective/Rationale:
Mutations in the LRRK2 gene are the most common known genetic risk factors for Parkinson's disease. Although we know that these mutations can cause Parkinson's disease... -
LRRK2 Cohort Consortium Resource Request, 2013Alpha-synuclein and Other Biomarkers in Biological Samples of LRRK2 Parkinson’s Disease
Objective/Rationale:
Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s pathology have been investigated in Parkinson’s disease (PD), and abnormal CSF protein levels (tau and phosphorylated tau, beta... -
Dyskinesia Challenge, 2013NOP Receptor Agonists for Preventing Levodopa-induced Dyskinesia
Objective/Rationale:
Dyskinesia (involuntary fractured, jerky movements) is a debilitating side effect of long-term levodopa treatment for Parkinson’s motor symptoms. Previous studies have... -
Cognition Biomarkers, 2013Alpha-synuclein and Cognitive Decline in Parkinson’s Disease
Objective/Rationale:
Variability in the SNCA gene (which encodes alpha-synuclein, the protein that clumps in Parkinson’s disease) is a major risk factor for PD. Using next-generation...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.